Dare Bioscience Files Prospectus Related To The Resale Of Up To 8,934,345 Shares Of Common Stock By Selling Stockholders
https://www.sec.gov/Archives/edgar/data/1401914/000149315226040265/forms-1.htm
Read original at benzingaStocks · News reference
Daré Bioscience Announces Publication Of Clinical Study Results From Its Proprietary Formulation Of Topical Sildenafil Cream, 3.6%, In Menopause In The Journal Of The Menopause Society; 3.6% Was Well Tolerated Across All Evaluated Doses In The Clinical Study, With Minimal Systemic Exposure
The peer-reviewed article, titled, "A phase 1, open-label, within-participant dose-escalation study to evaluate the safety and pharmacokinetics of topical sildenafil cream in healthy postmenopausal women,"
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 26, 2026, 12:47 PM
- Checked
- Aug 26, 2026, 12:47 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Dare Bioscience, Inc. (DARE)
Filed: 2026-08-17 AccNo: 0001493152-26-038649 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgar12 Health Care Stocks Moving In Friday's Intraday Session
Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular session. The company's market cap stands at $23.7 million. The company's, Q2 earnings came out yesterday.
Read original at benzinga